JPRN-jRCTs051200147CompletedPhase 4
Effect of empagliflozin on urinary albumin excretion and hypoxic injury biomarkers of early phase diabetic kidney disease - EUROBEAT Study
Makino Hisashi0 sites80 target enrollmentStarted: March 5, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 80
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to < 85age old (—)
- Sex
- All
Inclusion Criteria
- •20 years old or older, less than 85 years old with type 2 diabetes mellitus HbA1c of 6.5% or higher, and less than 10.0%
- •Urinary albumin excretion of 30mg/gCr or higher, and less than 300mg/gCr, and eGFR more than 30ml/min/1.72m2
- •No change in internal use of renin-angiotensin system inhibitors within 3 months of consent
- •No change in internal use of hypoglycemic drugs within 3 months of consent
Exclusion Criteria
- •BMI less than 18.5 kg/m2
- •Patients who diagnosed as chronic glomerulonephritis
- •Patients who are /want to pregnant, or are breast feeding
- •Patients taking SGLT2 inhibitors within 3 months of consent
- •Patients with heart failure of NYHA III or IV New York Heart Association functional classification
- •Patients who diagnosed as acute coronary syndrome or stroke within 3 months of consent
- •Patients who performed PCI or CABG within 3 months of consent
Investigators
Similar Trials
Completed
Not Applicable
Effect of canagliflozin on urinary albumin excretion in type 2 diabetic patients with microalbuminuria (pilot study)Type 2 diabetic patients with microalbuminuriaJPRN-UMIN000023959akakinen clinic Medical Corporation Kensei-kai20
Completed
Phase 1
Effect of empagliflozin/linagliptin on albuminuria and urinary liver-type free fatty acid binding protein in type 2 diabetic patients with chronic kidney disease: A randomized controlled trialT2DM and CKD patients with albuminuriaTCTR20210317005/A48
Recruiting
Phase 4
Effect of Tofogliflozin on Urine Albumin-to-Creatinine Ratio Compared to Metformin Hydrochloride in Diabetic Kidney DiseaseJPRN-jRCTs031210339Kuwahara Koichiro120
Active, not recruiting
Phase 1
Effects of empagliflozin on urine output and renal function in patients with acute heart failureMedDRA version: 20.0Level: LLTClassification code 10000803Term: Acute heart failureSystem Organ Class: 100000004849acute decompensated heart failureEUCTR2018-003692-35-DEFriedrich Schiller University Jena60
Completed
Not Applicable
The effect of empagliflozin on diuresis and neurohumoral factors in the patients with decompensated heart failure and diabetes mellitus: pilot studydecompensated heaat failure type 2 diabetes mellitusJPRN-UMIN000027431Department of Cardiology, National Hospital Organization Yokohama Medical Center15